Vol. IV · No. 19
Thursday, May 14, 2026
Issue: Spring · 2026
Established · MMXXVI
Geroevidence
— The evidence base for longevity medicine —
Indexed by PubMed · CTG · Cochrane
Editorial team · geroevidence.com
Subscription · app.geroevidence.com
Geroevidence · About

About Geroevidence

A clinical evidence service for longevity medicine. What we are, how we work, and what we will never claim to be.

§ Mission

Geroevidence exists because longevity medicine is moving faster than any physician can track manually.

New trials register. Papers publish. Evidence tiers move. A compound that was Emerging in January may be Moderate by March. A physician practicing at the frontier of geroscience cannot be expected to monitor PubMed, ClinicalTrials.gov, Cochrane, and bioRxiv daily across every intervention in their formulary.

We do that work. We synthesize, grade, and surface the evidence — clearly, without hype, with every claim linked to a primary source. The physician brings the clinical judgment. We bring the evidence.

§ Editorial principles
No clinical recommendations
Geroevidence synthesizes evidence. It does not tell physicians what to prescribe, what dose to use, or which patients to treat. That is clinical judgment — ours to support, never to replace.
Every claim cites a source
Nothing appears in a Geroevidence profile without a link to its primary source. No unsourced assertions. No summaries without citations.
Evidence strength is honest
We do not overstate. Emerging evidence is labeled Emerging. Moderate is not promoted to Strong because a compound is popular. The ladder moves when the evidence moves — not before.
Human review before publication
No automated content reaches subscribers without editorial review. Every alert, every profile update, every paper summary is checked before it publishes.
No conflicts of interest
Geroevidence does not accept advertising, sponsored content, or payments from pharmaceutical companies, supplement manufacturers, or any other commercial entity with an interest in the evidence we report.
Corrections are published
If we get something wrong we correct it publicly, with a dated correction notice, and update the relevant profile immediately.
§ How evidence grading works

Every intervention is graded on a four-tier ladder. The tier reflects the current weight of published human evidence — not animal data, not mechanistic plausibility, not expert opinion.

Strong
Phase III RCT evidence, or multiple concordant RCTs with society endorsement. The highest tier is reserved for evidence that would satisfy a regulatory standard.
Moderate
≥ 2 RCTs with concordant direction, or one large RCT with meta-analytic support. Real human trial evidence, but not yet at Phase III scale or with societal endorsement.
Emerging
A single RCT, or a pooled small-trial signal with consistent direction. Promising but insufficient for clinical confidence.
Insufficient
Pre-clinical evidence only, or early human signal without controlled trial support. Listed for completeness — not a basis for clinical decisions.
§ Data sources
PubMed / MEDLINE
Primary peer-reviewed literature. Indexed daily.
ClinicalTrials.gov
Trial registrations, status, and results. Synced daily.
Cochrane Library
Systematic reviews and meta-analyses.
bioRxiv / medRxiv
Pre-print literature. Clearly labeled as pre-print — not peer reviewed.
Conference abstracts
Major geroscience, cardiology, endocrinology, and oncology conferences. AGE, ADA, ACC, ASH, EASL.
§ Contact

For editorial questions, corrections, subscription enquiries, or press:

hello@geroevidence.com

We respond to all editorial correspondence within 48 hours.